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Abstract
Background: Magnesium plays a role in glucose and insulin homeostasis and evidence suggests that magnesium intake is
associated with insulin resistance (IR). However, data is inconsistent and most studies have not adequately controlled for
critical confounding factors.
Objective: The study investigated the association between magnesium intake and IR in normal-weight (NW), overweight
(OW) and obese (OB) along with pre- and post- menopausal women.
Design: A total of 2295 subjects (590 men and 1705 women) were recruited from the CODING study. Dietary magnesium
intake was computed from the Willett Food Frequency Questionnaire (FFQ). Adiposity (NW, OW and OB) was classified by
body fat percentage (%BF) measured by Dual-energy X-ray absorptiometry according to the Bray criteria. Multiple
regression analyses were used to test adiposity-specific associations of dietary magnesium intake on insulin resistance
adjusting for caloric intake, physical activity, medication use and menopausal status.
Results: Subjects with the highest intakes of dietary magnesium had the lowest levels of circulating insulin, HOMA-IR, and
HOMA-ß and subjects with the lowest intake of dietary magnesium had the highest levels of these measures, suggesting a
dose effect. Multiple regression analysis revealed a strong inverse association between dietary magnesium with IR. In
addition, adiposity and menopausal status were found to be critical factors revealing that the association between dietary
magnesium and IR was stronger in OW and OB along with Pre-menopausal women.
Conclusion: The results of this study indicate that higher dietary magnesium intake is strongly associated with the
attenuation of insulin resistance and is more beneficial for overweight and obese individuals in the general population and
pre-menopausal women. Moreover, the inverse correlation between insulin resistance and dietary magnesium intake is
stronger when adjusting for %BF than BMI.
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Introduction
Type 2 diabetes comprises 90% of all diabetic cases and has
become an ever increasing healthcare challenge as the number of
people affected reaches epidemic proportions [1]. The prevalence
of this condition is expected to reach over 438 million people
globally by the year 2030 and carries with it a significant fiscal
burden [2]. This is especially relevant to the Canadian province of
Newfoundland and Labrador considering it has one the highest
rates of diabetes and obesity in Canada. Currently, 9% of the
population of Newfoundland and Labrador struggle with diabetes
which corresponds to an annual cost of $254 million dollars [3].
The Canadian Diabetes Association has projected that by the year
2020 over 15% of Newfoundland and Labradorean’s will be
diabetic with an annual health care cost exceeding $360 million
dollars [3]. Although there is currently no medical intervention
capable of preventing the development of diabetes, simple lifestyle
modifications (such as increased physical activity, moderate weight
loss, and eating behavior modifications) have been shown to
attenuate the onset of type 2 diabetes [1,4]. However few studies to
date have investigated the association between dietary micronu-
trient intake and insulin function in the general population.
Magnesium, a cofactor required in over 300 enzymatic
reactions, is the fourth most abundant cation in the human body
involved with both glucose metabolism and insulin homeostasis
[5,6]. Although recent evidence has suggested that dietary
magnesium intake may play an important role in enhancing
insulin sensitivity, population based studies have found conflicting
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evidence regarding the potential benefit of dietary magnesium
intake. Several studies have correlated low dietary magnesium
intake [7–9] and serum magnesium [10] with increased insulin
resistance [11–13]. However, other studies do not support the
proposed protective effect that dietary magnesium can attenuate
the development of diabetes [14–16]. Of note, most studies have
not adequately controlled for adiposity in their analysis. Instead of
controlling for relative body fat, the majority of studies have
utilized the body mass index (BMI) which cannot accurately
distinguish fat mass from and fat-free mass [17]. Since adiposity is
the parameter most closely linked with the development of insulin
resistance [18], controlling for this important confounding factor is
critical. Therefore we designed the present study to investigate the
association between magnesium intake and insulin resistance in
the Canadian province of Newfoundland and Labrador, taking
into consideration age, gender, caloric intake, physical activity,
medication use, smoking status, menopause and adiposity.
Methods
Ethics Statement
Ethics approval was obtained from the Human Investigation
Committee, Faculty of Medicine, Memorial University, St. John’s,
Newfoundland, Canada. All subjects provided written and
informed consent before participation in this study.
Subjects
All 2330 subjects (600 men 1725 women) from the current study
are volunteers from the general population of Newfoundland and
Labrador and the cohort for our ongoing CODING (Complex
Diseases in the Newfoundland Population: Environment and
Genetics) Study. The CODING study is a large-scale nutrige-
nomics investigation [17,19,20]. Eligibility of participants for the
CODING study are based upon the following inclusion criteria: 1)
$19 yrs of age; 2) at least a third generation Newfoundlander; and
3) healthy, without any serious metabolic, cardiovascular, or
endocrine diseases. The primary method of subject recruitment for
the CODING study was the use of posters and handouts. This
literature was distributed throughout public facilities (offices,
hospitals, and gyms) in the city of St. John’s, Newfoundland and
Labrador. All subjects completed screening questionnaires pro-
viding information about physical characteristics, physical activity,
health status, and dietary practices. Anthropometrics, body
composition, and biochemical measurements were collected
following a 12 hour fast.
Physical Activity
Physical activity patterns were measured using the ARIC-
Baecke Questionnaire, which consists of a Work Index, Sports
Index, and Leisure Time Activity Index [21].
Dietary Magnesium Assessment
Dietary intake patterns of each participant were assessed using a
124 item semi-quantitative Willett Food Frequency Questionnaire
(FFQ) [22]. The Willett FFQ is one of the most commonly used
dietary questionnaires for large-scale epidemiologic studies [23].
The Willett FFQ obtains from subjects, the number of weekly
servings consumed of specific food item(s). NutriBase Clinical
Nutrition Manager (version 8.2.0; CybersoftInc, Phoenix, AZ)
software package was used to convert weekly serving values into
mean daily serving values to calculate the total daily intake of
magnesium (mg/day) for each individual. The nutritional infor-
mation, including dietary magnesium intake, was computed for all
subjects in the CODING study [19].
Anthropometric and Body Composition Measurements
Subjects were weighed (Health O Meter, Bridgeview, IL) to the
nearest 0.1 kg in standardized clothing (hospital gown). Height
was measured using a fixed stadiometer (nearest 0.1 cm). Body
mass index (kg/m2) was calculated as weight in kilograms divided
by participants’ height in meters squared. Whole body composi-
tion measurements including fat mass, lean body mass, and bone
mineral densities were measured using dual-energy X-ray absorp-
tiometry (DXA) Lunar Prodigy (GE Medical Systems, Madison,
WI). DXA can produce an accurate measurement of adipose tissue
within the body with a low margin of error. For this reason, DXA
is considered to be one of the most accurate measurements of
adiposity. DXA measurements were performed on subjects
following the removal of all metal accessories, while lying in a
supine position as previously described by us [17,19,20]. Body fat
percentage (%BF) is determined as a ratio of fat mass to total body
mass (Version 12.2 of the enCORE software). Quality assurance
was performed on our DXA scanner daily and the typical CV was
1.3% during the study period.
Biochemical Measurements
Serum concentrations of glucose and magnesium were mea-
sured on an Lx20 analyzer (Beckman Coulter Inc., Fullerton, CA)
using Synchron reagents. Serum insulin was measured on an
Immulite Immunoassay analyzer. Insulin resistance and beta cell
function were determined with the homeostasis model assessment
(HOMA), as described by Matthews et al [24].
HOMA{IR~((Fasting Insulin½mU=L
|Fasting Glu cos e½mmol=L)=22:5)
HOMA{b~((20|Fasting Insulin½mU=L)
=(Fasting Glu cos e½mmol=L{3:5))
Smoking, Medication and Menopausal Status
A self-administered screening questionnaire was used to collect
information about the subjects’ demographics, personal and family
medical history, medication use (yes or no), and smoking status (yes
or no). Women completed an additional questionnaire regarding
menstrual history and menopausal status (pre- or post-menopaus-
al) [17,19].
Statistical analysis
All data are reported as mean 6 standard deviation (SD) unless
otherwise stated. Participants with daily total caloric intake (kcal/
day) falling outside the range of 63SDs were considered outliers
and excluded from further analyses to account for possible errors
associated with over- or under-reporting of food intake on the
FFQ. Insulin, HOMA-IR, and HOMA-b were log-transformed to
normalize distributions and meet the assumptions of statistical
tests. The sample size for the study was 2295 participants (590
men, 1705 women). Differences in physical, biochemical, and
dietary patterns between men and women were assessed using
one-way ANOVA. Subjects were subdivided by adiposity into
Normal-Weight (NW), Overweight (OW), and Obese (OB) groups
based on %BF measured by DXA according to the age and
gender-specific criteria recommended by Bray [25]. Differences in
physical, biochemical, and dietary patterns among adiposity
groups was assessed using a one-way ANCOVA controlling for
Magnesium Intake and Insulin Resistance
PLOS ONE | www.plosone.org 2 March 2013 | Volume 8 | Issue 3 | e58278
age, gender, total caloric intake, physical activity, medication use
and smoking and menopause. As the number of underweight
subjects was too low (n = 28) to perform effective statistical
analysis, they were excluded from these analyses. To initially
explore the relationship between dietary magnesium and IR
(fasting glucose (mmol/l), insulin (pmol/l), HOMA-IR, HOMA-
b), participants were divided into a tertile (low, medium, or high)
based upon dietary magnesium intake (mg/day) which were
assessed using an ANCOVA controlling for age, gender, total
caloric intake, physical activity, medication use, smoking, meno-
pause and %BF. Subsequently, multiple regression analyses were
used to more rigorously explore the potential association of dietary
magnesium intake (g/kg body weight) with insulin resistance
(HOMA-IR) within the entire cohort and among men and women
adjusting for age, gender, caloric intake, physical activity,
medication use, smoking, menopause and %BF or BMI. However,
only caloric intake, physical activity, medication use, menopause
and %BF or BMI were statistically considered as confounding
variables within the regression models. In addition, due to the
significant interaction of adiposity and menopause on the
association between dietary magnesium intake and insulin
resistance, multiple regression analysis was performed among
normal-weight, overweight and obese subjects along with pre-
menopausal (n = 834) and post-menopausal (n = 577) women.
Multiple regression analyses were performed on subjects stratified
into tertiles (low, medium, or high) based upon both BMI and
%BF measured from DXA to assess the difference in their
adjustments on the relationship between dietary magnesium intake
and insulin resistance. Lastly, Binary logistic analysis was also
performed to explore the association between magnesium intake
(g/kg/day) and diabetes status. Diabetes status was defined by a
fasting glucose cutoff (glucose .7.0 mmol/L) together with those
individuals who reported they were diabetics. Under the
aforementioned definition, 102 subjects were labeled as diabetics
for this analysis. Age, gender, caloric intake, physical activity,
medication use, menopausal status, and smoking status were used
as covariates. However, only caloric intake, medication status and
age were statistically considered as confounding variables within
the binary logistic model. Some subjects had missing data in one
or more measurements. Five subjects did not disclose their
smoking status and eight subjects did not respond to the
medication use question. 1981 participants had all complete
dataset for all variables measured to be used for the ANCOVA
and multiple regression analysis. All statistical analyses were
performed with and without diabetic subjects; however none of the
results were not affected. All statistical analyses were performed
using PASW 19.0 (SPSS Inc., Chicago, IL). All tests were two-
sided and a p-value ,0.05 was considered to be statistically
significant.
Results
Physical, Biochemical, and Dietary Characteristics of
Normal-weight, Overweight, and Obese participants
Physical, biochemical, and dietary characteristics for men and
women along with those for normal-weight, overweight and obese
participants are presented in Table 1. Glucose, insulin, and
HOMA-IR were significantly greater for men than women, but
HOMA-b was significantly greater among women. In terms of
dietary intake, male participants had a significantly higher total
daily caloric and magnesium intake than females. However,
women had significantly greater magnesium intake (mg/day/kg)
per kilogram body weight than men. Insulin, glucose, HOMA-b,
and HOMA-IR values were greater among overweight and obese
subjects, which we have previously described [17,19,20]. Individ-
uals with the highest insulin, HOMA-IR and HOMA-b had the
highest levels of adiposity. In addition, subjects with highest levels
of adiposity had the lowest levels of magnesium intake (mg/day),
and magnesium intake per kilogram of body weight (mg/day/kg).
The findings remained significant after controlling for total age,
gender, caloric intake, physical activity, medication use, meno-
pausal status and smoking status. Serum magnesium was not
significantly different among adiposity groups (Table 1).
Insulin Resistance Among Low, Medium, and High
Dietary Magnesium Intake Groups
Physical, biochemical, and dietary characteristics were assessed
among a tertile (low, medium, or high) based upon dietary
magnesium intake (mg/day) (Table 2). Those individuals with the
highest magnesium intake had the lowest insulin, HOMA-IR and
HOMA-ß. Individuals with the lowest magnesium intake had the
highest fasting insulin levels, HOMA-IR, and HOMA-ß. The
findings remained significant after accounting for age, gender,
caloric intake, physical activity, medication use, smoking, meno-
pause and %BF. The dietary magnesium intake ranged from;
33.06 to 270.83 mg/day in the low dietary magnesium intake
group, 270.84 to 393.66 mg/day in the medium dietary magne-
sium intake group, and 394.07 to 2493.01 mg/day in the high
dietary magnesium intake group. Dietary magnesium intake per
kilogram of body weight ranged from; 0.43 to 5.3 mg/kg/day in
the low dietary magnesium intake group, 2.0 to 8.18 mg/kg/day
in the medium dietary magnesium intake group, and 3.17 to
44.84 mg/kg/day in the high dietary magnesium intake group.
Relationship between Dietary Magnesium and Insulin
Resistance
Unadjusted and adjusted linear regression analysis results of
dietary magnesium intake on insulin resistance are shown in
Table 3. There was a significant negative association between
dietary magnesium intake (g/day/kg) with HOMA-IR in the
entire cohort before and after adjusting for caloric intake, physical
activity, medication use, menopausal status and %BF or BMI. In
addition, the negative association between magnesium intake and
insulin resistance was greater having adjusted for adiposity (%BF)
over adjusting for BMI (Table 3). Multiple regression analysis of
the entire study cohort also revealed a significant interaction of
adiposity (%BF & BMI) with the negative association of
magnesium intake with insulin resistance. Therefore, multiple
regression analysis was performed on NW, OW and OB groups
based upon %BF according to the Bray Criteria (Table 3).
Magnesium intake was found to be significantly negatively
associated with HOMA-IR among all adiposity groups. This
inverse relationship was greater among overweight and obese
subjects and pre-menopausal women.
Relationship between Dietary Magnesium and Insulin
Resistance Among Low, Medium and High %BF and BMI
Unadjusted and adjusted linear regression analysis results of
dietary magnesium intake (g/day/kg) on insulin resistance among
low, medium and high BMI and %BF groups are shown in
Table 4. Magnesium intake was increasingly more negatively
associated with HOMA-IR the greater the adiposity (%BF) or
body mass index (BMI). Moreover, the negative association
between dietary magnesium intake and insulin resistance was
more prevalent according to a %BF classification than a BMI
classification (Table 4).
Magnesium Intake and Insulin Resistance
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Table 1. Physical, Biochemical, and Dietary Intake Characteristics of Normal-weight, Overweight, and Obese Participants.
Gender Percent Body Fat - Bray Criteria
Entire Cohort Male Female Normal Weight Overweight Obese p
(n =2295) (n =590) (n =1705) (n =547) (n=600) (n=781)
Age (yr) 3 43.16613 41.04614.4 43.92612.4 40.96614.34 45.02612.53 44.14612.3 ,0.001
Weight (kg)2 74.72616.5 86.86615.8 70.5614.5 64.63610.47 71.22611.37 86.12616.53 ,0.001
Height (cm)2 165.868.6 176.0966.5 162.2465.9 166.6868.5 165.3268.2 165.9869.0 NS
Waist (cm)2 93.07615 98.68613.9 91.13614.9 82.3569 90.8610.3 103.68614.5 ,0.001
Hip (cm)3 101.66611.9 100.8610.4 101.94612.4 92.7666.6 99.4867.2 110.25611.8 ,0.001
Waist-Hip Ratio2 0.9160.1 0.9860.1 0.8960.1 0.8960.1 0.9160.1 0.9360.1 ,0.001
BMI (kg/m2)2 27.165.2 27.9864.6 26.7965.4 23.1762.6 25.9762.9 31.1965.0 ,0.001
Total Body Fat (%)3 35.1769.1 26.3167.7 38.2267.5 26.8666.5 34.8665.7 42.1266.6 ,0.001
Glucose (mmol/L)2 5.1660.9 5.3561 5.0960.9 4.9860.7 5.1560.8 5.3361.1 ,0.001
Insulin (pmol/L)2 68.86667.7 73.53663 67.2669.3 50.58659.3 64.16672.8 84.74673.2 ,0.001
HOMA-IR2 2.3963.3 2.6563.4 2.363.3 1.7263.4 2.2163.6 3.063.4 ,0.001
HOMA-b3 133.996165 127.246129.4 136.256175.8 111.986176.3 122.756102.65 153.386204.4 ,0.001
Magnesium intake (mg/day)2 368.576210.4 394.296228.7 359.666203.3 415.966253.78 354.066171.3 351.56208.7 0.003
Magnesium intake (mg/day/kg)3 5.1563.1 4.6862.8 5.363.26 6.5163.9 5.0562.5 4.262.4 ,0.001
Serum Magnesium (mmol/L)2 0.8860.1 0.960.09 0.8760.08 0.8860.08 0.8860.08 0.8760.08 NS
Calories (kcal/day)2 1985.86878.6 2246.56982.7 1896.16821.7 2118.66937.1 1885.96764.62 19586897.4 ,0.001
1Data presented as mean 6 SD. Homeostasis model assessment of insulin resistance (HOMA-IR) and b-cell function (HOMA-b). Gender differences were assessed with a
one-way ANOVA. Subjects were also stratified into normal-weight, overweight and obese based upon %BF according to the Bray criteria (25). Adiposity differences were
assessed with an ANCOVA controlling for caloric intake, physical activity, medication use, and menopause. 2Significantly greater for men compared to women.
3Significantly greater for women compared to men. 4Statistical significance for one-way ANOVA and ANCOVA were set to p,0.05 (IBM SPSS Statistics 19).
doi:10.1371/journal.pone.0058278.t001
Table 2. Physical, Biochemical, and Dietary Intake Characteristics According to Magnesium Intake.
Dietary Magnesium Intake (mg/day)
Low Mg Intake Medium Mg Intake High Mg Intake p
(n=765) (n =765) (n=765) –
Age (yr) 43.78612.1 43.49612.3 42.22614.5 –
Weight (kg) 74.63616.7 74.46615.9 75.04616.8 NS
Height (cm) 164.768.2 165.6568.3 167.0769.0 NS
Waist (cm) 94.3615.0 92.94615.4 91.93614.5 NS
Hip (cm) 102.99611.8 101.78611.9 100.18611.9 NS
Waist-Hip Ratio 0.9160.08 0.9160.08 0.9260.09 NS
BMI (kg/m2) 27.465.3 27.0865.1 26.7965.2 NS
Total Body Fat (%) 36.6868.3 35.369.1 33.569.7 –
Glucose (mmol/L) 5.1860.8 5.1861.0 5.1761.0 NS
Insulin (pmol/L) 72.82668.6 71.45691.3 60.57642.9 ,0.001
HOMA-IR 2.4962.5 2.5965.2 2.0761.8 0.003
HOMA-b 142.376213.3 135.76182.0 116.24689.9 ,0.001
Magnesium intake (mg/day) 201.57648.6 328.85636.3 575.986224.1 ,0.001
Magnesium intake (mg/day/kg) 2.8360.9 4.5961.0 7.9963.6 ,0.001
Serum Magnesium (mmol/L) 0.8860.08 0.8860.07 0.8960.08 0.023
Calories (kcal/day) 1299.116409.9 1904.216440.42 2747.226928.49 –
1Data presented as mean 6 SD. Homeostasis model assessment of insulin resistance (HOMA-IR) and b-cell function (HOMA-b).
2Subjects were stratified into a tertile (low, medium and high) based upon magnesium intake (mg/day).
3Magnesium intake group differences were assessed with an ANCOVA controlling for caloric intake, physical activity, medication use, menopause and %BF.
4Statistical significance for one-way ANCOVA was set to p,0.05 (IBM SPSS Statistics 19).
doi:10.1371/journal.pone.0058278.t002
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Relationship between Dietary Magnesium and Diabetes
Status
Binary logistic analysis, performed to explore the association
between magnesium intake (g/kg/day) with diabetes status,
revealed that magnesium intake (g/kg/day) was significantly
negatively associated with diabetes status (n = 102, Unstandard-
ized b=2499.80, standard error 79.45, p,0.0001). Caloric
intake, medication status and age were statistically considered as
confounding variables within the binary logistic model.
Serum Magnesium and Markers of Insulin Resistance
The relationship between serum magnesium and insulin
resistance was also explored. Although serum magnesium
concentration concomitantly increased with dietary magnesium
intake, it was not found to be significantly associated with insulin
resistance in the Newfoundland population (data not shown).
Discussion
The noteworthy finding of the present investigation was a
beneficial dose dependent relationship between dietary magne-
sium intake and insulin resistance, independent of age gender,
total caloric intake, physical activity, medication use, menopause,
and adiposity. However, this favorable association was more
significant in overweight and obese subjects suggesting that this
population may be more sensitive to the beneficial effects of
dietary magnesium intake. Obesity, as a disorder, is a well-known
Table 3. Regression Models of Magnesium Intake on Insulin Resistance.
Unadjusted Adjusted Adjusted+%BF Adjusted+BMI
b b* p b b* p b b* p b b* p
HOMA-IR
Entire Cohort 221.03
(1.8)
20.232
(0.02)
,0.0001 233.75
(2.9)
20.374
(0.03)
,0.0001 219.33
(2.9)
20.214
(0.03)
,0.0001 211.65
(2.9)
20.129
(0.03)
,0.0001
Normal–weight 27.68
(2.6)
20.085
(0.03)
0.003 210.92
(4.0)
20.120
(0.05)
,0.0001 – – – – – –
Overweight 212.84
(3.9)
20.141
(0.04)
0.001 230.13
(6.9)
20.332
(0.08)
,0.0001 – – – – – –
Obese 223.79
(4.0)
20.262
(0.04)
,0.0001 245.97
(6.5)
20.506
(0.07)
,0.0001 – – – – – –
Pre-Menopause 215.07
(2.5)
20.188
(0.03)
,0.0001 235.32
(4.4)
20.439
(0.05)
,0.0001 220.4
(4.6)
20.254
(0.05)
,0.001 213.57
(4.4)
20.169
(0.05)
0.002
Post-Menopause 218.91
(3.5)
20.208
(0.04)
,0.0001 227.44
(4.6)
20.311
(0.05)
,0.0001 216.89
(4.8)
20.191
(0.05)
,0.001 27.32
(4.6)
20.083
(0.05)
NS
1Regression model adjusted for caloric intake, physical activity, medication use and menopausal status.
2b=Unstandardized Beta (standard error), b* = Standardized Beta (standard error), Magnesium intake (g/day/kg).
3Normal-weight, overweight and obese groups are based upon %BF according to the Bray criteria (25).
4Magnesium intake (Pre-Menopause 360.636209.8 mg/day, Post-Menopause 353.826192.9 mg/day) (Entire cohort, Normal-weight, Overweight, & Obese – See
Table.1).
5Statistical significance was set to p,0.05 (IBM SPSS Statistics 19).
doi:10.1371/journal.pone.0058278.t003
Table 4. Regression Models of Magnesium Intake on Insulin Resistance based upon %BF and BMI.
Body Fat Percentage
Low Medium High
b b* p b b* p b b* p
Entire Cohort
Unadjusted 214.98 (2.5) 20.165 (0.03) ,0.0001 217.36 (3.4) 20.191 (0.04) ,0.0001 220.98 (4.1) 20.231 (0.05) ,0.0001
Adjusted 214.30 (4.1) 20.157 (0.04) 0.001 223.39 (6.0) 20.258 (0.07) 0.0002 245.59 (6.48) 20.502 (0.07) 0.000
Body Mass Index
Entire Cohort
Unadjusted 23.89 (2.1) 20.043 (0.02) NS 212.4 (3.5) 20.137 (0.04) 0.0004 224.27 (4.7) 20.267 (0.05) ,0.0001
Adjusted 29.97 (3.5) 20.110 (0.04) 0.004 212.8 (6.4) 20.141 (0.07) 0.047 257.6 (7.9) 20.446 (0.08) 0.000
1Regression model adjusted for caloric intake, physical activity, medication use and menopausal status.Subjects were also stratified into a tertiles(Low, Medium and
High) based upon %BF and BMI.
2b=Unstandardized Beta (standard error), b* = Standardized Beta (standard error), Magnesium intake (g/day/kg).
3Magnesium intake (Low BMI 409.786243.5 mg/day, Medium BMI 353.246180.9 mg/day, High BMI 342.766196.1 mg/day) (Low %BF 387.56230.3 mg/day, Medium
%BF 360.546187.5 mg/day, High %BF 357.686210.7 mg/day).
4Statistical significance was set to p,0.05 (IBM SPSS Statistics 19).
doi:10.1371/journal.pone.0058278.t004
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condition which can place individuals at a significantly elevated
risk for impaired insulin action [26] and various metabolic
abnormalities such as hypertension, dyslipidemia, and a reduction
in glucose tolerance [26]. The functional relationship between
various hormones and obesity-related conditions is a significant
focus of obesity research, however diet composition has become
increasingly recognized and studied [2,4]. One study specifically
demonstrated that an increase in dietary magnesium can
significantly improve insulin sensitivity [27]. Magnesium has been
proposed to be functionally related to glucose metabolism through
an interaction with tyrosine-kinase activity on the insulin receptor
which is associated with the development of insulin resistance and
type 2 diabetes [28]. Studies have suggested that the effect of
dietary magnesium on decreasing markers of IR [11,12] and
development of type 2 diabetes is more pronounced in overweight
patients [11,12]. However, body fat percentage was not measured
in these studies. This is an especially important point to consider
when the relative amount and distribution of adipose tissue, both
important determinants of insulin sensitivity, cannot be deter-
mined by the body mass index [29–31].
In fact the majority of studies evaluating the association between
dietary magnesium and insulin resistance have only utilized BMI
when attempting to control for adiposity, bearing in mind that
percent body fat and BMI likely represent different physiological
entities. Having adjusted for the influence of %BF and BMI on the
association of dietary magnesium intake with insulin resistance, we
observed that this inverse association was stronger after having
adjusted for %BF than for BMI which further supports our
hypothesis. Considering that our laboratory and others have
revealed that BMI is not an accurate measure of body fat due to its
inability to differentiate fat mass from fat free mass [20,32,33], it is
implicit that BMI cannot represent adiposity. We found that
overweight and obese individuals, defined by a high resolution
adiposity measurement, are more sensitive to the beneficial effect
of magnesium intake on insulin resistance. Our current findings,
taken together with others of others [11,12] provides strong
evidence that overweight individuals, classified by either %BF or
BMI, could potentially benefit from an increase in magnesium
intake. It is possible that overweight and obese individuals are
better able to absorb and metabolize magnesium, thereby
enhancing its action at the insulin receptor and promoting insulin
sensitivity. To our knowledge, this study is the first large cross-
sectional study to systematically control for major confounding
factors including %BF when analyzing the relationship between
dietary magnesium intake and markers of insulin resistance. This
study is also the first investigation to observe that dietary
magnesium is more strongly associated with insulin resistance
when adjusting for %BF than BMI.
The association between dietary magnesium intake and insulin
resistance was examined with regards smoking [34], menopause
[12] and medication [35,36] as possible confounding factors for
this relationship. Evidence suggests that nicotine intake may
increase insulin resistance, however we did not find a significant
association of smoking status with HOMA-IR or magnesium
intake. In addition, during the regression model development
smoking status failed to reach statistical significance and was not
included in the regression model. Our data would suggest that
smoking is not a critical confounding factor regarding the
beneficial effect of dietary magnesium intake on insulin resistance
in the Newfoundland population. However, this finding may be
due to the significantly smaller sample size of smokers (n = 222) to
non-smokers (n = 1754) in our study cohort. Further study is
needed to elucidate the potential interaction of smoking on the
relationship of dietary magnesium intake and insulin resistance.
Medication status was significantly associated with insulin resis-
tance and there is evidence to suggest that various medications
inhibit magnesium re-absorption in the kidney which can result in
magnesium deficiency [35,36]. However, we were unable to find a
significant interaction of medication use on the inverse association
with magnesium intake and insulin resistance. Pre-menopausal
women were more significantly associated the beneficial effects of
magnesium intake on insulin resistance than post-menopausal
women. This finding is strengthened by the Shanghai Women’s
Health Study, designed to assess the prospective risk of type 2
diabetes, which found a statistically significant negative correlation
between magnesium intake and type 2 diabetes risk in pre-
menopausal women only [12]. We considered, since over 68% of
our post-menopausal women are medication users, that the lack of
association of magnesium intake with insulin resistance could be
drug related interference. However, this relationship remained
absent among post-menopausal women whether or not medication
status was included in the regression model. Therefore, our data
would suggest that the beneficial effects of magnesium intake are
less sensitive among post-menopausal women and further study is
needed to explore the physiological mechanism involved. Lastly,
we discovered that magnesium intake was significantly negatively
associated with diabetes. Considering that insulin resistance is a
significant clinical symptom of diabetes and that insulin resistance
was significantly inversely associated with magnesium intake this,
finding was not surprising. Our results suggest that the potential
beneficial influence of magnesium intake exists in a wide range of
populations from the general population to insulin resistance and
to those people struggling with struggling with diabetes in
Newfoundland and Labrador.
Aside from investigating the influence of %BF and BMI on the
association between magnesium intake and insulin resistance in
the general population and the influence that an adiposity status
defined by %BF has on this relationship, we also investigated
whether an adiposity status defined by BMI would have a different
effect than %BF on this association.
Considering that the adiposity status criteria for the World
Health Organization (WHO) [1] is considerably different from
that developed by Bray et al. [25], the association between dietary
magnesium intake and insulin resistance was examined among
low, medium and high tertiles according to %BF and BMI. Our
data revealed that the inverse relationship between dietary
magnesium intake and insulin resistance was progressively
stronger the greater the %BF or BMI. However, the aforemen-
tioned association was more significantly pronounced for con-
comitant increases in %BF over BMI. Consider that %BF is a
more direct measure of adiposity than BMI, together with our
current findings, we recommend that %BF be used when
considering adiposity as a factor.
The apparent protective role of magnesium on IR and type 2
diabetes has not been fully explained but is likely due to enhanced
insulin sensitivity through multiple mechanisms. For example,
phosphorylation of the tyrosine kinase enzyme of the insulin
receptor, required for post-receptor insulin sensitivity and subse-
quent insulin-mediated glucose uptake, is dependent on adequate
intracellular concentrations of magnesium [37]. As such, we also
chose to investigate the relationship between serum magnesium
and markers of IR; no significant association between them was
observed. Inconsistencies have been present in previous studies
examining this relationship, some supporting a negative correla-
tion [38,39] and others not [10]. One possible explanation for
these differences is that serum magnesium may not accurately
reflect intracellular magnesium levels, which may be low, even
when serum levels are within the normal range [14]. Additional
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studies are warranted to further clarify the relationship between
serum magnesium and markers of IR.
Our study had certain limitations, many of which were due to its
cross-sectional design. Firstly, our use of a FFQ to evaluate
patterns of dietary intake raises the possibility of recall bias by
subjects. However, the Willett FFQ chosen for this study is one of
the most commonly applied tool for the evaluation of dietary
intake in epidemiologic population-based studies [22,23]. In
addition, dietary magnesium is highly correlated with other
micronutrients and dietary components believed to affect insulin
sensitivity, such as vegetables, fruits, potassium, calcium, and fiber.
Thus, it is very difficult to separate their independent effects
[7,12]. In addition, to avoid over-adjustment, we opted not to
control for every available nutrient in our analysis. We did not
measure or account for magnesium supplementation regarding
daily magnesium intake, which could have potentially reduced the
strength of the inverse association found between magnesium
intake and IR makers. Furthermore, the reliability of serum
magnesium levels in recognizing total body magnesium deficiency
is unclear. Although intracellular magnesium concentrations are
believed to provide a more accurate estimation of magnesium
status, they are not generally easily measured [38]. Finally, our
study enrolled Caucasian Newfoundlanders, so our findings may
not be applicable to those from other ethnicities [16,40].
In summary, our cross-sectional study investigated the relation-
ship between dietary magnesium intake and insulin resistance
among 2295 Newfoundlanders and Labradoreans. To our
knowledge this study is the most comprehensive of its kind having
controlled for major confounding factors, most specifically being
dual energy x-ray absorptiometry (DXA) determined body fat
percentage. Our findings suggest that higher dietary magnesium
intake is associated with improved insulin sensitivity and this effect
is particularly beneficial for overweight and obese individuals in
the general population along with pre-menopausal women.
We also provide the first evidence that the association between
dietary magnesium and insulin resistance is more strongly
associated with %BF than BMI and the concomitant increase in
%BF over BMI. Due to the fact that %BF more accurately
represents adiposity than BMI, caution should be taken when
attempting to utilize BMI as a measure of adiposity. Further large-
scale prospective studies, where body fat is adequately accounted
for and which enroll various ethnic groups, are needed to further
elucidate the role of dietary magnesium in improving insulin
function and preventing diabetes.
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